Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy

Background: A systemic inflammatory marker, the modified Glasgow prognostic score (mGPS), could predict outcomes in non-muscle-invasive bladder cancer (NIMBC). We aimed to investigate the predictive power of mGPS in oncological outcomes in HG/G3 T1 NMIBC patients undergoing Bacillus Calmette–Guérin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferro, Matteo, Tătaru, Octavian Sabin, Musi, Gennaro, Lucarelli, Giuseppe, Abu Farhan, Abdal Rahman, Cantiello, Francesco, Damiano, Rocco, Hurle, Rodolfo, Contieri, Roberto, Busetto, Gian Maria, Carrieri, Giuseppe, Cormio, Luigi, Del Giudice, Francesco, Sciarra, Alessandro, Perdonà, Sisto, Borghesi, Marco, Terrone, Carlo, La Civita, Evelina, Bove, Pierluigi, Autorino, Riccardo, Muto, Matteo, Crisan, Nicolae, Marchioni, Michele, Schips, Luigi, Soria, Francesco, Terracciano, Daniela, Papalia, Rocco, Crocetto, Felice, Barone, Biagio, Russo, Giorgio Ivan, Luzzago, Stefano, Ludovico, Giuseppe Mario, Vartolomei, Mihai Dorin, Mistretta, Francesco Alessandro, Mirone, Vincenzo, de Cobelli, Ottavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947693/
https://www.ncbi.nlm.nih.gov/pubmed/35328139
http://dx.doi.org/10.3390/diagnostics12030586
Descripción
Sumario:Background: A systemic inflammatory marker, the modified Glasgow prognostic score (mGPS), could predict outcomes in non-muscle-invasive bladder cancer (NIMBC). We aimed to investigate the predictive power of mGPS in oncological outcomes in HG/G3 T1 NMIBC patients undergoing Bacillus Calmette–Guérin (BCG) therapy. Methods: We retrospectively reviewed patient’s medical data from multicenter institutions. A total of 1382 patients with HG/G3 T1 NMIBC have been administered adjuvant intravesical BCG therapy, every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months. The analysis of mGPS for recurrence and progression was performed using multivariable and univariable Cox regression models. Results: During follow-up, 659 patients (47.68%) suffered recurrence, 441 (31.91%) suffered progression, 156 (11.28%) died of all causes, and 67 (4.84%) died of bladder cancer. At multivariable analysis, neutrophil to lymphocyte ratio [hazard ratio (HR): 7.471; p = 0.0001] and erythrocyte sedimentation rate (ESR) (HR: 0.706; p = 0.006 were significantly associated with recurrence. mGPS has no statistical significance for progression (p = 0.076). Kaplan–Meier survival analysis showed a significant difference in survival among patients from different mGPS subgroups. Five-year OS was 93% (CI 95% 92–94), in patients with mGPS 0, 82.2% (CI 95% 78.9–85.5) in patients with mGPS 1 and 78.1% (CI 95% 60.4–70) in mGPS 2 patients. Five-year CSS was 98% (CI 95% 97–99) in patients with mGPS 0, 90% (CI 95% 87–94) in patients with mGPS 1, and 100% in mGPS 2 patients. Limitations are applicable to a retrospective study. Conclusions: mGPS may have the potential to predict recurrence in HG/G3 T1 NMIBC patients, but more prospective, with large cohorts, studies are needed to study the influence of systemic inflammatory markers in prediction of outcomes in NMIBC for a definitive conclusion.

Ejemplares similares